問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of General Internal Medicine

Division of Family Medicine

更新時間:2023-09-19

詹其峰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

2Cases

2025-08-29 - 2031-12-31

Phase III

Active
A double-blind, randomized, placebo-controlled, multicenter trial was conducted to evaluate the use of Olpasiran in participants with elevated lipoprotein (a) levels to prevent the first major cardiovascular event.
  • Condition/Disease

    The risk of a first major cardiovascular event is associated with elevated lipoprotein (a) (Lp[a]).

  • Test Drug

    AMG 890 (Olpasiran)

Participate Sites
9Sites

Recruiting9Sites

2023-09-01 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Terminated3Sites